Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trial

Fig. 2

Tumor Response. a Waterfall plot of best percent change from baseline in the sum of longest diameters of target lesions in patients with RET-fusion positive NSCLC. b Swimmer plot according to dose level in patients with RET-fusion positive NSCLC. Best response is evaluated as per RECIST 1.1. NE not evaluable, NSCLC non-small-cell lung cancer, PD progressive disease, PR partial response, RET rearranged during transfection, SD stable disease

Back to article page